TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Summary

This is a phase 1/1b open label, multicenter dose escalation and dose expansion study to investigate the safety, tolerability and anti-tumor activity of TPST-1120, a small molecule selective antagonist of PPARα (peroxisome proliferator activated receptor alpha) as monotherapy and in combination with a systemic anticancer agent, nivolumab, an anti-PD1 antibody, in subjects with advanced solid tumors.

Timeline

Start

2019-03-20

Primary completion

2022-09-07

Completion

2022-09-07

Drugs

Indications